TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Primary Glaucoma Treatment Trial in Kenya and South Africa - SLT vs. Medication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Consent to inclusion and participation in trial.~  * Characteristic glaucomatous changes in the optic disc. The presence of a focal or diffuse area of optic disc rim loss, so that the neuroretinal rim tissue in any quadrant is less than 5% of the disc diameter in that meridian. Extensive loss of neuroretinal rim tissue with marked optic disc cupping giving a cup disc ratio greater than 0.6.~ * A measured intraocular pressure greater than or equal to 21 mmHg and less than or equal to 30mmHg on at least one visit before the time of entry into the study as measured by Goldmann applanation tonometry.~ * Adequate visualization of angle structures (i.e. clear media and cooperative patient)~ * Black African patients~Exclusion Criteria:~* • Unwillingness to participate in the study~  * Inability/unwillingness to give informed consent~ * Unwillingness to accept randomisation~ * Patient less than 20 years of age~ * Anterior segment neovascularisation~ * Past trauma to the eye or ocular adnexae~ * Retinal or optic nerve neovascularisation~ * Aphakia or pseudophakia~ * Previous ocular surgery Evidence of ocular disease other than glaucoma that might affect the measurements of IOP, assessment of visual function, visual field testing would likely require cataract surgery within 12 months of randomization on systemic medications known to -IOP (e.g. steroids) Pregnancy or female of childbearing age who may be pregnant at time of treatment (LMP).~ * Anyone who is not Black African race

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Selective laser trabeculoplasty (Type: ACTIVE_COMPARATOR): Selective laser trabeculoplasty
- Prostaglandin analogue (Type: ACTIVE_COMPARATOR): Prostaglandin analogue topical medical therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed stage I or II primary operable breast cancer~  * Surgery planned within next 1-4 weeks~* Hormone receptor status:~  * Estrogen receptor positive or unknown~ * No known estrogen receptor negative tumor~ * Unknown progesterone receptor status eligible~PATIENT CHARACTERISTICS:~Age:~* Any age~Sex:~* Female~Menopausal status:~* Premenopausal or postmenopausal~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* No bleeding diathesis not compatible with an IM depot injection~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective non-hormonal contraception during and for 2-3 months after study~* No other prior or concurrent malignancy except adequately treated basal cell carcinoma of the skin or cancer of the uterine cervix~* No psychological, familial, sociological, or geographical condition that would preclude study~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* At least 2 months since prior ICI 182780~Radiotherapy:~* No prior radiotherapy to primary tumor~Surgery:~* See Disease Characteristics~Other:~* No other concurrent preoperative therapy for breast cancer

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sputum-derived Cellular Targets After Xolair (Omalizumab)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Physician diagnosed asthma~* Lung function (one or more of the following documented in the 5 years before enrollment or demonstration during screening) 1. Bronchial hyper responsiveness (BhR) confirmed by ≥ 12% improvement in FEV1 post bronchodilator within the previous 5 years, or 2. Methacholine PC20 \< 16mg/dl within the previous 5 years~* Severity Criteria: Moderate-persistent asthma defined by the American Thoracic Society (ATS)~* Asthma Control: Partly or uncontrolled asthma according to GINA 2012 guidelines (at least three of the following features: daytime symptoms more than 2 times/week, limitation of activities, nocturnal symptoms, need for rescue inhaler \> 2 times/week, FEV1 \<80% predicted)~* Stable use of moderate-high dose inhaled corticosteroids in previous 3 months (definition derived from GINA 2012 guidelines: e.g. fluticasone propionate \>250 mcg/day, budesonide \> 400mcg/day)~* Ability to perform induced sputum maneuvers~* Presence of elevated allergen IgE to any perennial aeroallergen~Exclusion Criteria:~* Pulmonary function: FEV1 ≤ 70% predicted~* Any major chronic illness including but not limited to Chronic Obstructive Pulmonary Disease (COPD), uncontrolled hypertension, coronary artery disease, bronchiectasis, congestive heart failure, stroke, cystic fibrosis, insulin-dependent diabetes mellitus, renal failure, liver disorders, immunodeficiency state, or other condition that would interfere with participation in the study~* Current or \> 10 pack a year pack-year tobacco use~* Any investigational study within previous 1 month~* Inability to perform baseline measurements~* Inability to contact by telephone~* Pregnancy at screening and failure to use double barrier pregnancy protection in woman of childbearing age~* Hypersensitivity reaction to omalizumab in the past~* Exceeds limits of dosing table (IgE \<30 or 700 IU/ml) or body weight of \<30 or \> 150kg~* Systemic corticosteroids within the previous month~* Known malignant neoplasm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Denosumab on the Pharmacokinetics of Etanercept

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women (postmenopausal is defined as no vaginal bleeding or spotting for at least 12 months)~* Low bone mineral density (BMD) as determined by screening BMD T-scores of the lumbar spine (L1 to L4), or total evaluable vertebrae (if fewer than L1 to L4), or total hip ≤ -1.0~* Receiving a 50 mg dose of etanercept once weekly ≥ 6 months prior to screening and expected to continue etanercept treatment at this dose and frequency through end of study (EOS)~* If currently taking methotrexate (MTX), receiving a stable dose (7.5 to 20 mg/week) of MTX ≥ 8 weeks prior to screening~* Willing and able to take ≥ 1,000 mg elemental calcium and ≥ 400 IU vitamin D daily upon enrollment~Exclusion Criteria:~* Type 1 diabetes; OR poorly controlled Type 2 diabetes (hemoglobin A1c (HbA1c) \> 8.0% at screening; HbA1c ≤ 8.0% within 6 months of screening is acceptable if supporting laboratory documentation is available)~* History of heart failure, coronary artery bypass graft, or cardiac arrhythmia; OR history of acute coronary syndrome~* Comorbid autoimmune disease, demyelinating disease, or hematologic abnormalities~* History of joint replacement in hand and/or wrist; OR history of fused joint in hand and/or wrist~* Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw; OR active dental or jaw condition that requires oral surgery, or non-healed dental/oral surgery; OR planned invasive dental procedure(s) during the course of the study~* Previous exposure to denosumab

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Etanercept + Denosumab (Type: EXPERIMENTAL): Participants received etanercept 50 mg subcutaneously once weekly for 25 weeks. On study day 8, participants were administered a single 60 mg subcutaneous injection of denosumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Histologically confirmed non-Hodgkin's lymphoma by brain biopsy~* Patients with inconclusive biopsy or patients who are not candidates for biopsy must have typical CT scan or MRI of the brain AND meet ≥ 1 of the following criteria:~  * Positive cerebrospinal fluid cytology for lymphoma OR a monoclonal lymphoid population as defined by cell surface markers or immunoglobulin gene rearrangement studies~ * Biopsy-proven involvement of the vitreous or uvea if cells are apparent in the posterior chamber or vitreous by ophthalmological examination~* Bideminsionally measurable disease, defined as contrast-enhancing tumor ≥ 1 cm by pretreatment MRI/CT scan~  * Meningeal or vitreous involvement constitutes evaluable but not measurable disease~ * If an excisional, rather than a needle biopsy was done, measurable disease must be present on a postoperative scan (not a PET-CT scan)~* ECOG performance status 0-3~* Absolute granulocyte count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin ≤ upper limit of normal (ULN)~* SGOT ≤ 2.0 times ULN~* Creatinine clearance ≥ 50 mL/min~* Negative pregnancy test~* Fertile patients must use effective contraception~Exclusion criteria:~* Pregnant or nursing~* HIV-1 positivity~* Other malignancy within the past 5 years except basal cell skin cancer or any carcinoma in situ~* Pre-existing immunodeficiency~* Hepatitis B surface antigen positivity~* Systemic lymphoma (as determined by pre-registration CT scans and physical examination)~* Prior chemotherapy or radiotherapy for primary central nervous system lymphoma~* Prior organ or bone marrow transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab + standard chemotherapy (Type: EXPERIMENTAL): Rituximab + high dose methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine. Patients with meningeal involvement will receive additional methotrexate and leucovorin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Nutrition in Upper Gastrointestinal (GI) Cancer Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Surgery for Upper GI cancer~* Age over 18~* Informed consent~Exclusion Criteria:~* Major swallowing disorders~* Dementia or other psychological state precluding compliance and understanding of research protocol~* Pre-existing enteral or parenteral nutrition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nutrition (Type: EXPERIMENTAL): Pre-operative immunonutritrion, pre-operative glucose load, post-operative early immunonutrition
- Control (Type: NO_INTERVENTION): No immunonutrition, no glucose load, no early enteral immunonutrition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Success of External Cephalic Version Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients included are those with singleton pregnancies of at least 37 weeks gestation in nonvertex presentation with no contraindication for a vaginal delivery.~* Membranes must be intact with a minimum of a 2x2 pocket and Category 1 non-stress test.~Exclusion Criteria:~* All patients with a contraindication for a vaginal delivery will be excluded from the study.~* Patients with gross fetal anomalies or uterine malformations.~* Patients with contraindications to neuraxial anesthesia or allergies to any of the study medications will also be excluded.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Spinal anesthesia immediately for ECV. (Type: ACTIVE_COMPARATOR): The patient will have a spinal administered by the on call anesthesiologist using standard protocol (intrathecal bupivacaine 7.5 mg). The patient will then be administered 0.25 mg Terbutaline subcutaneously and the ECV will be attempted. Under ultrasound guidance the provider will attempt to lift the breech upward from the pelvis with one hand and guide the head with the other hand to produce a forward roll. If forward roll fails, a backward roll somersault may be attempted. ECV attempt will be abandoned if there is significant fetal bradycardia, discomfort to the patient, or if the procedure cannot be completed easily with these maneuvers. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
- Spinal anesthesia if no intervention fails for ECV. (Type: EXPERIMENTAL): The patient will be administered terbutaline 0.25 mg subcutaneously and the version will be attempted using the same procedure as above. If successful, the patient will be monitored for 30 minutes and discharged if fetal and maternal status is reassuring. If the attempt fails, the patient will be administered spinal anesthesia as above and the same maneuvers will be attempted. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least 18 years old male or female~* chronic lymphoid leukaemia, any Rai stage~* 25-OH-Vitamin-D3 level between 10 and 30 ng/mL~Exclusion Criteria:~* serum calcium \> 2,60 mmol/l~* 24 hour calcium urine excretion \> 0,1 mmol/kg/day~* serum phosphate \> 1,45 mmol/l~* eGFR \< 30 ml/min/1,73m2~* nephrolithiasis~* receiving parenteral vitamin-D3 in past 6 months~* activated vitamin-D3 treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): no treatment
- Cholecalcipherol (Type: ACTIVE_COMPARATOR): Treatment with 180 000 IU cholecalcipherol monthly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fluid Challenges and Microcirculation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing a high-risk abdominal surgery~* Patients equipped with a minimally invasive cardiac output monitoring device in order to optimize fluid administration~Exclusion Criteria:~* Atrial fibrillation~* Ejection fraction \<40%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3478006 in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Are overtly healthy male or female Japanese or non-Japanese participants, as determined by medical history and physical examination~* Women not of childbearing potential~* Are aged 18 to 55 years (20 to 55 years for Japanese participants), inclusive, at screening~Exclusion Criteria:~* Have clinically significant abnormal electrocardiogram (ECG) results~* Have persistent abnormal blood pressure or pulse rate, as determined by the investigator~* Have evidence of orthostatic hypotension, defined as a decrease in systolic or diastolic blood pressure greater than or equal to (≥)20 millimeters of mercury (mmHg) or ≥10 mmHg, respectively~* Have significant history or presence of cardiovascular, respiratory, hepatic, ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorders~* Have a history or presence of mononeuropathy, polyneuropathy, or autonomic neuropathy~* Have significant allergies to humanized monoclonal antibodies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 10 milligram (mg) LY3478006 - Intravenous (IV) (Type: EXPERIMENTAL): Participants received single dose of 10 mg LY3478006 administered IV. Due to early termination of the study Cohort 2 to 6 (30 mg, 100 mg, 300 mg, 600 mg, and 1000 mg LY3478006 IV) were not explored for safety reasons following dosing of the first 4 participants in Cohort 1.
- Placebo - IV (Type: PLACEBO_COMPARATOR): Participants received single dose of placebo administered IV. Placebo IV Cohorts 2 through 6 were not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
- 100 mg LY3478006 - Subcutaneous (SC) (Cohort 7) (Type: EXPERIMENTAL): 100 mg LY3478006 cohort 7 SC dose was not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
- Placebo - SC (Cohort 7) (Type: PLACEBO_COMPARATOR): Placebo cohort 7 SC dose were not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Starvation Time Prior to Gastroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years~* Sufficient knowledge of Danish to understand the written information~* legally competent patients~Exclusion Criteria:~* Patients with a history of pyloric stenosis (narrowing of the transition from stomach to the duodenum)~* Incapacitated patients~* Patients with daily vomiting.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 2 (Type: NO_INTERVENTION): 6 hours of total fast for all solid and liquid food / drinks
- Group 1 (Type: EXPERIMENTAL): * 6 hour fast from all solid foods and milk beverages~* 2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~* Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility